Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olanzapine augmentation in treatment-resistant depression
NCT00273624Phase 3Withdrawn
- Sponsor
- University Hospital Freiburg
- Start
- Jun 2005
- Primary completion
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of olanzapine in major depressive disorder (MDD), sponsored by University Hospital Freiburg. Planned start Jun 2005; status: withdrawn.
02
Drugs
olanzapine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00273624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00273624.